Advertisement

Topics

Boehringer Ingelheim axes biosimilars development outside US

07:02 EST 5 Dec 2018 | pharmaphorum

Boehringer Ingelheim has said it has axed development of its biosimilars outside Europe, focusing instead on getting its Humira near-copy on the US market as soon as possible. BI got its biosimilar of AbbVie’s inflammatory diseases drug Humira (ad...

Original Article: Boehringer Ingelheim axes biosimilars development outside US

NEXT ARTICLE

More From BioPortfolio on "Boehringer Ingelheim axes biosimilars development outside US"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...